{"id":1009129,"date":"2026-10-12T06:48:09","date_gmt":"2026-10-12T10:48:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-and-bausch-health-announce-appointment-of-thomas-j-appio-as-interim-bausch-lomb-ceo-expect-to-raise-full-year-2026-guidance\/"},"modified":"2026-10-12T06:48:09","modified_gmt":"2026-10-12T10:48:09","slug":"bausch-lomb-and-bausch-health-announce-appointment-of-thomas-j-appio-as-interim-bausch-lomb-ceo-expect-to-raise-full-year-2026-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-and-bausch-health-announce-appointment-of-thomas-j-appio-as-interim-bausch-lomb-ceo-expect-to-raise-full-year-2026-guidance\/","title":{"rendered":"Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance"},"content":{"rendered":"

<\/p>\n

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance<\/b><\/p>\n

VAUGHAN, Ontario–(BUSINESS WIRE<\/a>)–
\nBausch + Lomb Corporation (NYSE\/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE\/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb.<\/p>\n

\nAppio was appointed chairman of the Bausch + Lomb Board of Directors in August 2026. The Board believes Appio\u2019s deep knowledge of the business, global leadership experience and longstanding connection to Bausch + Lomb position him well to build on the company\u2019s momentum and lead its next phase of growth.<\/p>\n

\n\u201cThe opportunity to lead Bausch + Lomb is both a privilege and a responsibility that I embrace with great enthusiasm,\u201d said Appio. \u201cOur company is built on the strength of our people, the quality of our portfolio and a relentless commitment to serving customers and patients around the world. With a strong foundation, we are well positioned to build on our momentum and deliver sustainable growth.\u201d<\/p>\n

\nAppio has served as CEO of Bausch Health since 2022. Under his leadership, Bausch Health (excluding Bausch + Lomb) has delivered 13 consecutive quarters of year-over-year growth in revenue and adjusted EBITDA (non-GAAP).1<\/sup> He held several leadership roles within Bausch + Lomb prior to the company\u2019s initial public offering in 2022. Appio joined Bausch + Lomb in 2010 as managing director, China, and in 2016 assumed the role of president, Bausch + Lomb International.<\/p>\n

\nBrent Saunders, who has served as Bausch + Lomb CEO since 2023, and the Board of Directors mutually agreed that Saunders will depart the company.<\/p>\n

\n\u201cWhen I returned to Bausch + Lomb, I believed this company had tremendous potential,\u201d said Saunders. \u201cToday, it is stronger, more focused and better positioned for the future, with a clearer strategy, a more robust pipeline and significant opportunities ahead. The progress we’ve made reflects the talent, passion and commitment of colleagues across the organization, and I’m proud of everything we’ve accomplished together.\u201d<\/p>\n

Preliminary Update on 2026 Guidance2<\/sup><\/b><\/p>\n

\nBased on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1<\/sup> guidance.3<\/sup> The companies are currently in a blackout period and will provide additional details when they report third-quarter results on Oct. 28.<\/p>\n\n\n\n\n
\n

1<\/sup><\/p>\n<\/td>\n

\n

\nThis is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the \u201cNon-GAAP Information\u201d section of this news release.<\/p>\n<\/td>\n<\/tr>\n

\n

2<\/sup><\/p>\n<\/td>\n

\n

\nThe preliminary update on guidance in this news release speaks only as of the date given, October 12, 2026, and will not be further updated or affirmed unless and until each company publicly announces updated or affirmed guidance. Distribution or reference of this news release following October 12, 2026, does not constitute the company reaffirming guidance. There is no assurance that Bausch + Lomb or Bausch Health will achieve its forecasted results within the relevant period or otherwise. Actual results may differ materially from these estimates as a result of actual quarter-end results, the completion of normal quarter-end accounting procedures and adjustments, including the execution of our internal control over financial reporting, the completion of the preparation and management\u2019s review of our financial statements for the relevant period and the subsequent occurrence or identification of events prior to the release of our financial results for the relevant period. See the \u201cForward-looking Statements\u201d section for further information.<\/p>\n<\/td>\n<\/tr>\n

\n

3<\/sup><\/p>\n<\/td>\n

\n

\nThe increase in anticipated full-year adjusted EBITDA (excluding Acquired IPR&D) is a result of continued strong business performance in the third quarter of 2026 and anticipated stronger business performance for the remainder of 2026.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

About Bausch + Lomb<\/b><\/p>\n

\nOur mission is simple \u2013 we help people see better to live better, all over the world. For nearly two centuries we\u2019ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we\u2019re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com<\/a> and connect with us on Facebook<\/a>, Instagram<\/a>, LinkedIn<\/a>, X<\/a> and YouTube<\/a>.<\/p>\n

About Bausch Health<\/b><\/p>\n

\nBausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com<\/a> and connect with us on LinkedIn.<\/a><\/p>\n

Forward-looking Statements<\/b><\/p>\n

\nThis news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, \u201cforward-looking statements\u201d). Forward-looking statements may generally be identified by the use of the words \u201canticipates,\u201d \u201chopes,\u201d \u201cseeks,\u201d \u201cintends,\u201d \u201cexpects,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cforecasts,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cstrive,\u201d \u201cestimates,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201ccontinue,\u201d \u201cpending\u201d or \u201cproposed\u201d and positive and negative variations or similar expressions and phrases and statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result. Forward-looking statements include statements regarding the companies\u2019 full-year 2026 guidance (including expected increases to such guidance) and Bausch + Lomb\u2019s ability to deliver sustainable growth and create lasting value for shareholders. These statements are based upon the current expectations and beliefs of management and are provided for the purpose of providing additional information about such expectations and beliefs, and readers are cautioned that these statements may not be appropriate for other purposes. The expected increase to full-year 2026 guidance is based on certain material factors and assumptions, including preliminary, unaudited third-quarter 2026 results that remain subject to completion of quarter-end closing and review procedures, stronger business performance for the remainder of 2026, prevailing foreign exchange rates and other assumptions. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb\u2019s and Bausch Health\u2019s filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) and the Canadian Securities Administrators (the \u201cCSA\u201d), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Neither Bausch + Lomb nor Bausch Health undertake any obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.<\/p>\n

Non-GAAP Information<\/b><\/p>\n

\nTo supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), Bausch + Lomb and Bausch Health use certain non-GAAP financial measures and ratios. Management of each company use these non-GAAP measures and ratios as key metrics in the evaluation of each company\u2019s performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. Bausch + Lomb and Bausch Health believe these non-GAAP measures and ratios are useful to investors in their assessment of each company\u2019s operating performance and the valuation of each company. In addition, these non-GAAP measures and ratios address questions the companies routinely receives from analysts and investors, and in order to assure that all investors have access to similar data, the companies have determined that it is appropriate to make this data available to all investors. These measures and ratios do not have any standardized meaning under GAAP and other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to similar non-GAAP measures and ratios of other companies. We caution investors not to place undue reliance on such non-GAAP measures and ratios, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.<\/p>\n

\nBausch + Lomb does not provide a reconciliation of forward-looking Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)2<\/sup> to GAAP net income (loss) attributable to Bausch + Lomb Corporation, and Bausch Health does not provide a reconciliation of forward-looking Adjusted EBITDA (non-GAAP)2<\/sup> to GAAP net income (loss), in each case due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. These amounts may be material and, therefore, could result in the projected GAAP measure or ratio being materially different or less than the projected non-GAAP measure or ratio.<\/p>\n

Specific Non-GAAP Measures<\/i><\/b><\/p>\n

\nAdjusted EBITDA excluding Acquired IPR&D<\/p>\n

\nEBITDA (non-GAAP) is Net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest, income taxes, depreciation and amortization. Adjusted EBITDA (non-GAAP) is EBITDA (non-GAAP) further adjusted for the items described below. Management believes that Adjusted EBITDA (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the company measures the business internally and sets operational goals and incentives. In particular, the company believes that Adjusted EBITDA (non-GAAP) focuses management on the company\u2019s underlying operational results and business performance. As a result, the company uses Adjusted EBITDA (non-GAAP) both to assess the actual financial performance of the company and to forecast future results as part of its guidance. Management believes Adjusted EBITDA (non-GAAP) is a useful measure to evaluate current performance. Adjusted EBITDA (non-GAAP) is intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the company\u2019s executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.<\/p>\n

\nAdjusted EBITDA (non-GAAP) is Net income (loss) attributable to Bausch + Lomb Corporation (its most directly comparable U.S. GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization and further adjusted for the following items:<\/p>\n